|Videos|September 7, 2021
Emerging Agents for R/R CLL
Experts discuss emerging agents for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
Advertisement
Episodes in this series
Advertisement
Related to this article
Pooled results from the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials confirmed the efficacy of pirtobrutinib in treatment-naive CLL.
A post hoc analysis found similar safety outcomes for fixed-duration regimens containing acalabrutinib/venetoclax across age groups in treatment-naive CLL.
In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
FDA Grants Fast Track Designation to Pan-RAS Molecular Glue ERAS-0015 for Metastatic Pancreatic Adenocarcinoma
3
Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC
4
The OncFive: Top Oncology Articles for the Week of 8/16
5